Ascidian Therapeutics

Risk score

57
Large logo of Ascidian Therapeutics

Headquarters

Flag of United States of AmericaUnited States of America

Ascidian Therapeutics is a company in the field of biotechnology that focuses on the treatment of human illnesses through the process of RNA rewriting. The company's therapeutic strategy revolves around the modification of exons at the RNA level, enabling precise post-transcriptional alteration of genetic material. This modification aims to generate fully functional proteins of optimal quantities, within specific cells, and at the appropriate timings. Ascidian Therapeutics is actively involved in the exploration and preclinical projects aimed at addressing various conditions, such as retinal ailments, neurological issues, neuromuscular disorders, and genetically determined diseases.